Form 4: Zevra Therapeutics Director Tamara A. Favorito Granted Stock Options

Director Tamara A. Favorito received stock options for 49,200 shares of Zevra Therapeutics, Inc. at an exercise price of $4.89.

Summary

• Tamara A. Favorito, a director of Zevra Therapeutics, Inc., was granted stock options to purchase 49,200 shares of the company's common stock.
• The options were granted on May 13, 2024, with an exercise price of $4.89 per share, which equals the closing price of ZVRA on that date.
• The grant was awarded as compensation for Favorito's service on the board of directors, according to the company's non-employee director compensation policy.
• The options vest on the earlier of (i) the first anniversary of the grant date, (ii) one day prior to the first annual meeting of the Issuer's stockholders following the date of grant or (iii) immediately prior to a change in control of the Issuer, subject to continued service on the vesting date.
• The options expire on May 12, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine compensation practice. The sentiment is neutral to slightly positive as it aligns director interests with shareholders.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Industry Context

Stock option grants are a common form of compensation for directors of publicly traded companies, aligning their interests with those of shareholders and incentivizing them to work towards increasing the company's value.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary significantly across the pharmaceutical industry depending on company size, stage of development, and performance.
• Comparing Zevra's director compensation to peers like BioCryst Pharmaceuticals or Catalyst Pharmaceuticals would provide a better understanding of whether the grant is in line with industry standards.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders' equity if the options are exercised.
• The grant incentivizes the director to work towards increasing shareholder value.

Key Dates